Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
PhotonPharma raised $2.5M in Seed funding to support the Phase I clinical trial of Innocell™, an innovative therapy for advanced ovarian cancer.
PRIVATEAug 22, 2024•almost 2 years ago
Amount Raised
$2.5 Million
Round Type
Seed
Fort CollinsBiotechnology
Description
PhotonPharma, a biopharmaceutical company based in Fort Collins, CO, secured $2.5M in Seed funding. The funds will be used to advance the Phase I clinical trial of Innocell™, aimed at treating advanced ovarian cancer.
Company Information
Company
PhotonPharma
Location
3185 RAMPART ROAD
Fort Collins, Colorado, United States
About
PhotonPharma is dedicated to developing innovative autologous cancer therapies that leverage the body's immune system to fight disease. With a focus on personalized medicine, the company's lead product, Innocell™, aims to provide a safe and effective therapy for a wide range of solid organ tumors. In February 2024, PhotonPharma received FDA clearance for the company's first Phase 1 study in the US: a first-in-human clinical study for stage III/IV ovarian cancer treatment with the investigational autologous vaccine therapy, Innocell™. The company has partnered with the City of Hope in Los Angeles to conduct the study. The Phase 1 clinical trial for Innocell™ will evaluate its safety, tolerability, and immune response indicators in patients with Stage III/IV ovarian cancer. PhotonPharma anticipates initiating patient enrollment in the near future.
Don't miss PhotonPharma's next move
Get an email the moment PhotonPharma raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contact
Verified contactsAlan R., Director
Predictive Intelligence
Strategic
ML-powered predictions for PhotonPharma's next move
Fort CollinsBiotechnology